Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma

NCT03107988 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.

NCT NCT03107988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03107988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Phase
Phase 1
Overall status
Completed
Start date
September 5, 2017
Completion date
January 31, 2025
Enrollment
65 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma